Zynex Inc

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. The company also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zynex Inc (ZYXI) achieves record highs in Q4 2022

Zynex Inc (ZYXI) delivered strong financial performance in Q4 2022 and full-year 2022, projecting continued growth in 2023. The company's focus on innovation, regulatory milestones, and operational efficiency positions it well for future success.

Zynex Inc reports robust Q1 earnings, eyes revenue growth

Zynex Inc's Q1 2023 performance reflects strong revenue growth and increased orders, supported by strategic initiatives like stock buybacks.
While facing challenges in scaling the sales force and navigating market dynamics, the company is well-positioned to leverage opportunities for expansion and innovation.
Investors can look forward to continued revenue growth, product development, and potential market expansion as Zynex pursues its growth targets.

Zynex Inc reports record revenue and FDA clearances, reaffirms guidance

Zynex Inc delivered robust financial results in Q2 2023, showcasing consistent profitability and revenue growth across its divisions.
The company's focus on product innovation, FDA clearances, and strategic financial moves underscores its commitment to sustained growth and market leadership.
While facing potential challenges, Zynex Inc remains optimistic about its future outlook, aiming to capitalize on market opportunities and drive continued success.

Zynex reports record revenue and growth outlook, driven by innovation

Zynex Inc (ZYXI) delivered strong financial results in Q3 2023, driven by revenue growth, operational efficiency, and strategic product innovations.
The company's focus on noninvasive pain management solutions and commitment to regulatory milestones underscore its growth potential and market positioning.
While facing challenges such as market competition and operational scalability, Zynex's strengths in financial performance and innovation present opportunities for sustained success.

Zynex Inc (ZYXI) reports record revenue and explores strategic alternatives

Zynex Inc (ZYXI) delivered a strong performance in 2023, marked by record revenue, profitability, and operational achievements, positioning the company for continued growth and success.
While facing challenges related to strategic decision-making and operational execution, Zynex remains well-positioned to capitalize on opportunities for revenue expansion, product innovation, and market leadership.
With a focus on financial stability, product diversification, and strategic growth initiatives, Zynex is poised to navigate challenges, leverage opportunities, and drive value for shareholders in the upcoming year.

Zynex Inc reports revenue growth and FDA clearance success

Zynex Inc (ZYXI) demonstrated solid financial performance in Q1 2024, with revenue growth and positive cash flow.
The company's focus on product innovation, sales expansion, and revenue diversification positions it well for future growth.
While facing challenges such as revenue delays and strategic uncertainties, Zynex remains optimistic about its growth prospects and market opportunities.

Zynex Inc reports strong Q2 performance, eyes $200M revenue target

Zynex Inc delivered a strong Q2 2024 performance with revenue growth, improved sales efficiency, and a positive outlook for the year, targeting $200 million in total revenue.
While facing challenges in revenue diversification and sales force refinement, Zynex maintains a solid gross profit margin and a focus on operational excellence.
The company's Monitoring Solutions division shows promise, with ongoing product milestones and plans for FDA submission, indicating future growth potential and market expansion.
Strategic management of challenges and capitalizing on opportunities position Zynex well for sustained growth and profitability in the evolving healthcare market.

Zynex Inc reports strong Q3 performance and eyes growth opportunities

Zynex Inc's Q3 2024 performance reflects revenue growth, profitability, and strategic reinvestment in the business.
While facing challenges in decision-making and operational efficiency, the company is well-positioned for growth.
Opportunities in expanding sales, launching new products, and exploring partnerships pave the way for future success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Zynex, Inc. engages in the design, manufacture, and marketing of medical devices. It sells electrotherapy medical devices used for pain management and rehabilitation. It also develops a new blood volume monitor for use in hospitals and surgery centers. The company was founded by Thomas Sandgaard in 1996 and is headquartered in Englewood, CO.

LOS ANGELES, CA / ACCESSWIRE / March 12, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Zynex, Inc. ("Zynex" or "the Company") (NASDAQ:ZYXI) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

ENGLEWOOD, Colo. , March 10, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) , an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter  and full-year 2022 financial results on Monday, March 13, 2023.

Zynex, Inc. Reschedules Release of Fourth Quarter and Full Year 2022 Financial Results

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Zynex, Inc. (NASDAQ: ZYXI) resulting from allegations that Zynex may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Zynex securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Zynex, Inc. Investors with Losses in Excess of $100K to Inquire About Class Action Investigation – ZYXI

LOS ANGELES--(BUSINESS WIRE)---- $ZYXI #ZYXI--The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc.

INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Zynex, Inc. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company's possible violations of the federal securities laws.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Zynex, Inc. (ZYXI) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) investors concerning the Company's possible violations of federal securities laws. On March 6, 2023, Zynex announced that the Company was postponing release of its fourth quarter and full year financial results and conference call initially scheduled for March 6, 2023 to allow additional time to complete its year-end closing procedures.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Zynex, Inc. (ZYXI) on Behalf of Investors

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate.

The Law Offices of Frank R. Cruz Announces Investigation of Zynex, Inc. (ZYXI) on Behalf of Investors

ENGLEWOOD, Colo. , March 6, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will postpone the release of its fourth quarter and full year financial results and conference call initially scheduled for Monday, March 6, 2023 at 4:15 p.m.

Zynex, Inc. to Postpone Fourth Quarter and Full Year 2022 Financial Results Release and Conference Call

ENGLEWOOD, Colo. , Feb. 23, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the company will report fourth quarter  and full-year 2022 financial results on Monday, March 6, 2023.

Zynex, Inc. to Announce Fourth Quarter and Full Year 2022 Financial Results

ENGLEWOOD, Colo. , Feb. 21, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced the lease of a new 41,000 square foot facility to accommodate Zynex Monitoring Solution's (ZMS) current and expected future growth.

Zynex Leases New Facility to Accommodate Growth

ENGLEWOOD, Colo. , Feb. 17, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that it is set to join the MSCI USA Small Cap Index according to the list of additions posted by MSCI on February 9, 2023.

Zynex Announces Inclusion in MSCI USA Small Cap Index

Amgen

Azenta

Globus Medical

1Life Healthcare

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Could Blast Off This Month - Azenta (NASDAQ:AZTA), Amgen (NASDAQ:AMGN)

FG Merger Corp

DENVER--( BUSINESS WIRE )--Intrinsic LLC (“Intrinsic”), a fast-growing valuation and transaction advisory firm with employees located across a dozen U.S. cities, announced today that its Transaction Opinions practice issued two fairness opinions for publicly traded clients in 2022. Garrett Wilson, Managing Director commented, “We are proud and grateful that our publicly traded clients are clearly recognizing the best-in-class execution and value proposition that has been Intrinsic's calling card for years in the private equity, family office and high net worth clientele communities. Evolving Delaware Court of Chancery legal precedents and increasing SEC scrutiny make independent fairness opinions a wise investment as a part of Boards of Directors' financial diligence for significant or related party M&A. We look forward to continuing our strong momentum as a trusted provider of fairness opinions for publicly traded companies.”

Intrinsic's Growing Transaction Opinions Practice Issued Two Public Company Fairness Opinions in 2022

ENGLEWOOD, Colo. , Feb. 1, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation and patient monitoring, today reported it will be hosting a blood donation drive on February 1, 2023 at its headquarters in Englewood, CO in partnership with Vitalant, the nation's largest independent, nonprofit blood services provider.

Zynex Monitoring Announces Community Blood Drive and Research Collaboration Trial for its Fluid Monitoring System

Products sold in the past by Zynex for pain management have failed to penetrate the market. Zynex's new products are radically different from their predecessors: more specific and innovative.

Zynex Is A Quality Company, But You Must Pay For Quality

ENGLEWOOD, Colo. , Jan. 31, 2023 /PRNewswire/ -- Zynex, Inc. (Nasdaq: ZYXI) an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced The Healthcare Technology Report has recognized Zynex in The Power 500 Healthcare Technology Companies.

Zynex Recognized in The Power 500 Healthcare Technology Companies

ENGLEWOOD, Colo. , Jan. 17, 2023 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced preliminary results for fourth quarter 2022 and reiterated full year guidance.

Zynex Reports Preliminary Fourth Quarter 2022 Results

ENGLEWOOD, Colo. , Dec. 22, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been ranked 11th on Forbes list of America's Best Small Companies for 2023.

Zynex Ranks 11th in Forbes List of "America's Best Small Companies 2023"

Celsius Holdings

Clearfield

Dow Inc

Enphase Energy

Futu Holdings

Honeywell

McDonald's

Brigham Minerals

Merck

NIKE

Northern Oil and Gas

Nuvalent

AiHuiShou International Co Ltd

SPDR S&P 500 ETF Trust

TAL Education Group

Tidewater

Visa

Viridian Therapeutics

Verizon

Zymeworks Inc

Two new Breakout Stocks for Week 50 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +131.5% YTD. This week 1 of 4 high frequency breakout picks gained over 10% in less than a week with peak gains in VITL +10.4% while PBT hit +6.22% and CPRX +4.4%.

MDA Breakout Stocks Week 50 - December 2022: Short-Term Picks To Give You An Edge

Bank of America

MarineMax

According to recent data from Bank of America's ( BAC , Financial) BofA Securities, the small-cap stocks on the Russell 2000 index are now trading at their lowest average forward price-earnings ratio since 2009. The Russell 2000 is also down 19% year to date versus the S&P 500's 16% loss.

3 Small-Cap Bargains Gurus Are Buying

Zynex, Inc.'s business is inflation-resistant, and the monitor division could be a game changer. Quarterly results were positive, and Zynex continues to operate at its best.

Zynex: A Growing Stock In A Bearish Market

ENGLEWOOD, Colo. , Nov. 21, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced that the Company's management will participate in the Piper Sandler 34th Annual Healthcare Conference.

Zynex Medical to Participate in Piper Sandler 34th Annual Healthcare Conference

G-III Apparel Group

Goldman Sachs

Intel

JPMorgan Chase & Co

Lattice Semiconductor

Two new Breakout Stocks for Week 47 with better than 10% short-term upside potential and one Dow 30 Pick. Average cumulative returns now up to +123.7% YTD. This week 2 of 4 picks gained 10%+ in less than a week with FUTU +23.6% and FREY 14.0% of the high frequency breakout movers. VIPS peaked at +9.64%.

MDA Breakout Stocks Week 47 - Short-Term Picks To Give You An Edge

ENGLEWOOD, Colo. , Nov. 17, 2022 /PRNewswire/ -- Zynex, Inc. (NASDAQ: ZYXI ), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, rehabilitation, and patient monitoring, today announced it has been ranked 416th in revenue growth among all companies in the U.S. and Canada for revenue growth between 2018 and 2021 on Deloitte's Technology Fast 500.

News for Zynex Inc Stock (ZYXI)